Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds

Executive Summary

Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.

You may also be interested in...



Commercial Coverage For Specialty Drugs Lacks Consistency, Study Finds

Coverage decisions are also often more restrictive than drug labeling, according to researchers from Tufts.

Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase

Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Topics

Related Companies

UsernamePublicRestriction

Register

SC126091

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel